The company has received approval from US FDA for the Arformoterol Tartrate inhalation solution.
The company posted a sharp rise in net profit at Rs 208.8 crore in Q3FY22 against Rs 78.08 crore in Q3FY21, and revenue more than doubled to Rs 540.21 crore from Rs 224.37 crore YoY.
The footwear company recorded a sharply higher profit at Rs 72.32 crore in Q3FY22 against Rs 26.4 crore in Q3FY21, while revenue surged to Rs 841.3 crore from Rs 615.6 crore YoY.
Latent View Analytics
The company recorded a profit of Rs 49.92 crore in Q3FY22 against a profit of Rs 22.45 crore in Q3FY21. Revenue surged to Rs 107.75 crore from Rs 78.25 crore YoY.
Jindal Steel & Power
The company posted a lower profit at Rs 1,621.68 crore in Q3FY22 against Rs 2,439.89 crore in Q3FY21, and revenue increased to Rs 12,524.86 crore from Rs 9,280.54 crore YoY.
The company reported a lower profit at Rs 829.6 crore in Q3FY22 against Rs 1,134 crore in Q2FY22, but revenue rose to Rs 29,866.6 crore from Rs 28,326.4 crore QoQ.
Data Patterns (India)
The company clocked a profit of Rs 8.96 crore in Q3FY22 against a loss of Rs 4.4 crore in Q3FY21. Meanwhile, revenue nearly doubled to Rs 43.84 crore from Rs 22.41 crore YoY.
The company reported a higher-than-expected profit at Rs 2,049.8 crore but missed revenue expectations. Revenue came in at Rs 5,873.7 crore.
The company completed a reorganisation review and concluded that the current structure is optimal. It also announced the capital allocation policy.
The capital-raising committee of the bank will meet on Friday to consider a proposal to seek the approval of investors for early redemption of certain Basel II- compliant lower tier-II and upper tier-II bonds.
FII & DII DATA
FII Net SELL – 1967.89 cr
DII Net BUY – 1115 cr